Brind.

Dasher Neuroscience is developing the YA-101 compound for the treatment of Multiple System Atrophy (MSA).

1 report, 1 independent Updated Jul 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Dasher Neuroscience is developing the YA-101 compound for the treatment of Multiple System Atrophy (MSA).

Who's involved

What this event is mainly about
MSA

Keep exploring

The entities involved

  • MSA

    Czech company

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • manilatimes.netDasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA)